RiboX is a biotechnology company specializing in the discovery and development of fully engineered circular RNA therapeutics—a new class of RNA medicines designed to overcome the limitations of traditional mRNA therapies. By focusing on circular RNA, RiboX aims to unlock the full potential of RNA-based treatments, offering innovative solutions for various medical conditions. Globally, RiboX operates from its headquarters in Shanghai, China, with additional offices in Beijing, Princeton (USA), and Rehovot (Israel). The company collaborates with international research institutions and industry partners to advance its therapeutic platforms and bring cutting-edge treatments to the global market. In Israel, RiboX's presence in Rehovot positions it within one of the country's leading hubs for scientific research and innovation. This strategic location enables RiboX to engage with Israel's vibrant biotech ecosystem, fostering collaborations with local universities, research centers, and biotech companies. Through these partnerships, RiboX contributes to the advancement of RNA-based therapeutics, leveraging Israel's renowned expertise in medical research and technology development. By integrating global operations with local collaborations, RiboX is at the forefront of developing next-generation RNA medicines, striving to make significant contributions to healthcare worldwide and particularly within Israel.